GlassScriptPhysician profile
Barbara Addi
NPI 1730798406
$6,019.30
in general payments reported to CMS, 2019-2025
34 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $648 · 2023: $1,530 · 2024: $1,947 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717 · Education: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,717.32 |
| Education | $516.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,378.90 | 2022-2025 | Rybrevant, Erleada, Akeega |
| Astrazeneca Pharmaceuticals LP | $624.24 | 2021-2025 | Enhertu, Calquence, Tagrisso |
| Abbvie INC. | $524.67 | 2023-2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $377.15 | 2023-2025 | |
| Seagen INC. | $365.08 | 2021-2023 | Adcetris |
| Glaxosmithkline, LLC. | $330.11 | 2024-2025 | Jemperli, Ojjaara, Blenrep |
| Novocure INC. | $288.17 | 2025 | Optune Lua (Novottf-200t), Optune Gio |
| E.R. Squibb & Sons, L.L.C. | $270.23 | 2023 | Pomalyst, Opdualag |
| Geron Corporation | $188.59 | 2025 | Rytelo |
| Array Biopharma INC | $169.42 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Eisai INC. | $146.66 | 2023-2024 | |
| Pharmaessentia USA Corporation | $143.46 | 2024 | Besremi |
| Amgen INC. | $141.76 | 2024-2025 | Blincyto, Kyprolis, Blincyto |
| Pfizer INC. | $124.79 | 2025 | |
| Gilead Sciences, INC. | $117.92 | 2023 | Trodelvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $99.95 | 2024 | |
| Celgene Corporation | $99.54 | 2023-2025 | Reblozyl, Opdivo, Pomalyst |
| Mirati Therapeutics, INC. | $99.46 | 2023-2024 | Krazati |
| Astellas Pharma US INC | $75.46 | 2023-2024 | Padcev, Xospata |
| Regeneron Healthcare Solutions, INC. | $63.38 | 2023-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $57.89 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $57.28 | 2023-2024 | Xpovio |
| Beigene USA, INC. | $33.90 | 2024 | Brukinsa |
| Adc Therapeutics America, INC. | $26.98 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $26.37 | 2023 | Epkinly |
| Merck Sharp & Dohme LLC | $25.22 | 2024 | Keytruda |
| Daiichi Sankyo INC. | $22.92 | 2023 | Enhertu |
| Coherus Oncology, INC. | $22.65 | 2024 | |
| Genentech USA, INC. | $21.88 | 2024 | Venclexta |
| Servier Pharmaceuticals LLC | $21.88 | 2024 | |
| Astellas Pharma Global Development | $20.71 | 2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $19.68 | 2024 | |
| Legend Biotech USA INC. | $17.97 | 2024 | |
| Janssen Scientific Affairs, LLC | $15.03 | 2023 | Tecvayli, Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Addi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.